Pharmacological Properties ofN-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease
Open Access
- 24 January 2008
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 325 (1), 77-88
- https://doi.org/10.1124/jpet.107.130443
Abstract
Amiloride improves mucociliary clearance (MC) by blocking airway epithelial sodium channels (ENaC) and expanding airway surface liquid (ASL). However, the low potency and rapid absorption of amiloride by airway epithelia translated into a short duration of efficacy as an aerosolized therapy for cystic fibrosis (CF) patients. To improve ENaC blocker CF pharmacotherapy, a more potent and durable ENaC blocker tailored for aerosol delivery was synthesized. Parion compound N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02) was tested for potency and reversibility of ENaC block, epithelial absorption and biotransformation, selectivity, durability of ASL expansion under isotonic and hypertonic conditions in canine and human CF bronchial epithelial cells, and drug dissociation on ENaC in Xenopus oocytes. Short-circuit current assessed compound potency and reversibility, patch-clamp recordings of ENaC current assessed drug off-rate (koff), a gravimetric method and confocal microscopy measured mucosal water retention and ASL height, and drug absorption and biotransformation were assessed using liquid chromatography-mass spectrometry. Amiloride and 552-02 were tested in vivo for MC activity in sheep immediately and 4 to 6 h after aerosol dosing. Compared with amiloride, compound 552-02 was 60 to 100-fold more potent, it was 2 to 5-fold less reversible, it was slower at crossing the epithelium, and it exhibited a 170-fold slower koff value. 552-02 exhibited greater ASL expansion over 8 h in vitro, and it was more effective than amiloride at increasing MC immediately and 4 to 6 h after dosing. When combining hypertonic saline and 552-02, a synergistic effect on ASL expansion was measured in canine or CF bronchial epithelia. In summary, the preclinical data support the clinical use of 552-02 +/– hypertonic saline for CF lung disease.This publication has 37 references indexed in Scilit:
- Rationale for Hypertonic Saline Therapy for Cystic Fibrosis Lung DiseaseSeminars in Respiratory and Critical Care Medicine, 2007
- Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosisPediatric Pulmonology, 2007
- Design, Synthesis, and Structure−Activity Relationships of Novel 2-Substituted Pyrazinoylguanidine Epithelial Sodium Channel Blockers: Drugs for Cystic Fibrosis and Chronic BronchitisJournal of Medicinal Chemistry, 2006
- Abnormal ion content, hydration and granule expansion of the secretory granules from cystic fibrosis airway glandular cellsExperimental Cell Research, 2005
- Cystic FibrosisThe New England Journal of Medicine, 2005
- Evaluation of Second Generation Amiloride Analogs as Therapy for Cystic Fibrosis Lung DiseaseThe Journal of pharmacology and experimental therapeutics, 2004
- Identification of Amino Acid Residues in the α, β, and γ Subunits of the Epithelial Sodium Channel (ENaC) Involved in Amiloride Block and Ion PermeationThe Journal of general physiology, 1997
- Effect of Amiloride on Sodium-Calcium Exchange Activity in Rat Cardiac MyocytesPharmacological Research, 1993
- A Pilot Study of Aerosolized Amiloride for the Treatment of Lung Disease in Cystic FibrosisThe New England Journal of Medicine, 1990
- Amiloride and its analogs as tools in the study of ion transportThe Journal of Membrane Biology, 1988